Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
Colorcon
Mallinckrodt
Moodys

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,504,030

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,504,030 protect, and when does it expire?

Patent 6,504,030 protects PLAVIX and is included in one NDA.

Protection for PLAVIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-five patent family members in forty-three countries.

Summary for Patent: 6,504,030
Title: Polymorphic form of clopidogrel hydrogen sulphate
Abstract:Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-.alpha.-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5 -acetate and a process for its preparation
Inventor(s): Bousquet; Andre (Sisteron, FR), Castro; Bertrand (Kremlin-Bicetre, FR), Saint-Germain; Jean (Sisteron, FR)
Assignee: Sanofi-Synthelabo (Paris, FR)
Application Number:10/177,092
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,504,030
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 6,504,030

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us PLAVIX clopidogrel bisulfate TABLET;ORAL 020839-001 Nov 17, 1997 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us PLAVIX clopidogrel bisulfate TABLET;ORAL 020839-002 Sep 20, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,504,030

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1344   Start Trial
Argentina 014854   Start Trial
Austria 222256   Start Trial
Australia 4048399   Start Trial
Australia 752170   Start Trial
Bulgaria 104987   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKinsey
Merck
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.